Biofrontera (NASDAQ:BFRI) Issues Earnings Results

Biofrontera (NASDAQ:BFRI) announced its quarterly earnings data on Thursday. The company reported ($0.05) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.10) by $0.05, Zacks reports. Biofrontera had a negative return on equity of 515.34% and a negative net margin of 25.66%.

Here are the key takeaways from Biofrontera’s conference call:

• Q2 revenue rose 33% to $12.0 million, driven by approximately 30% Ameluz unit-volume growth and the 2025 price increase. Gross margin expanded to about 80%, while adjusted EBITDA improved to near breakeven from a $5.1 million loss a year earlier.
• Commercial momentum continued, with first-half order count up 18.6%, average tubes per order up 10%, and the installed base reaching approximately 801 lamps across 740 physician offices. Management said more than 81% of customers that made large pre-price-increase purchases reordered in the first half.
• The ITC exclusion order bars Biofrontera from importing or selling the current RhodoLED XL lamp and restricts Ameluz sales for use with that device. The company is pursuing an appeal and a minor lamp redesign, but must still obtain clearance from border authorities; approximately 243 XL lamps are affected.
• Biofrontera expects potential FDA approval for superficial basal cell carcinoma on September 28, 2026, with a planned first-quarter 2027 launch using its existing lamps and sales force. It also plans to file an expanded actinic keratosis indication by the end of the third quarter and is advancing an acne program toward Phase III.
• Liquidity remains a constraint, with $4.7 million in cash at June 30 and a going-concern qualification in the financial statements. Management expects to reach cash-flow breakeven in 2026 but may need a working-capital facility, while future clinical development depends on available funding.

Biofrontera Stock Performance

Shares of NASDAQ BFRI traded up $0.01 during trading on Thursday, reaching $1.26. 1,042,053 shares of the company traded hands, compared to its average volume of 356,424. The firm has a 50 day simple moving average of $1.07 and a 200-day simple moving average of $0.98. The company has a quick ratio of 1.09, a current ratio of 1.20 and a debt-to-equity ratio of 0.78. The stock has a market capitalization of $16.12 million, a PE ratio of -1.30 and a beta of 0.78. Biofrontera has a 52-week low of $0.55 and a 52-week high of $1.40.

Institutional Inflows and Outflows

An institutional investor recently raised its position in Biofrontera stock. Rosalind Advisors Inc. boosted its stake in Biofrontera Inc. (NASDAQ:BFRI) by 51.5% in the second quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 976,448 shares of the company’s stock after purchasing an additional 332,055 shares during the period. Biofrontera makes up approximately 0.3% of Rosalind Advisors Inc.’s holdings, making the stock its 27th largest position. Rosalind Advisors Inc. owned about 9.63% of Biofrontera worth $695,000 at the end of the most recent reporting period. Institutional investors and hedge funds own 10.08% of the company’s stock.

Wall Street Analyst Weigh In

A number of brokerages recently issued reports on BFRI. Weiss Ratings upgraded shares of Biofrontera from a “sell (e+)” rating to a “sell (d-)” rating in a research note on Wednesday, July 15th. Wall Street Zen raised Biofrontera to a “hold” rating in a research report on Saturday, July 18th. Finally, Zacks Research upgraded Biofrontera from a “strong sell” rating to a “hold” rating in a research note on Monday, August 3rd. One investment analyst has rated the stock with a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat, the stock has a consensus rating of “Hold”.

About Biofrontera

Biofrontera AG is a specialty biopharmaceutical company focused on the research, development and commercialization of products for dermatological applications. The company’s core expertise lies in photodynamic therapy (PDT), a treatment modality that uses a photosensitizing agent activated by a specific light source to target diseased skin cells while sparing surrounding healthy tissue.

The flagship product in Biofrontera’s portfolio is Ameluz (aminolevulinic acid hydrochloride 10 % gel), which has received marketing approval in the European Union for treatment of actinic keratosis and basal cell carcinoma, and in the United States for actinic keratosis.